34
|
van Vollenhoven RF, Hahn BH, Tsokos GC, Lipsky P, Gordon RM, Fei K, Lo KH, Chevrier M, Rose S, Berry P, Yao Z, Karyekar CS, Zuraw Q. Efficacy and Safety of Ustekinumab in Patients with Active Systemic Lupus Erythematosus: Results Through 2 Years of an Open-Label Extension in a Phase 2 Study. J Rheumatol 2021; 49:380-387. [PMID: 34853089 DOI: 10.3899/jrheum.210805] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/19/2021] [Indexed: 11/22/2022]
Abstract
OBJECTIVE To evaluate long-term efficacy and safety of ustekinumab through 2 years in patients with active systemic lupus erythematosus (SLE). METHODS This was a placebo-controlled (Week24) phase 2 study in 102 patients with seropositive active SLE. Patients were randomized to ustekinumab (~6 mg/kg single IV infusion, then 90 mg SC every 8 weeks) or placebo, added to background therapy. Placebo patients initiated ustekinumab (90mg SC Q8W) at Week24. Patients could enter an optional open-label study extension after Week40 (final ustekinumab administration at Week104). Efficacy assessments included SRI-4, SLEDAI-2K, PGA, and CLASI. Observed data are reported for the extension period. The final efficacy assessment was at Week112; safety was monitored through Week120. RESULTS In this subset of patients who entered the study extension, 24 in the ustekinumab group and 14 in the placebo-crossover group completed study treatment. At Week112, 79% and 92%, respectively, had an SRI-4 response, 92% in both groups had ≥4-point improvement from baseline in SLEDAI-2K score, 79% and 93%, respectively, had ≥30% improvement from baseline in PGA, 86% and 91%, respectively, had ≥50% improvement in active joint (pain and inflammation) count, and 79% and 100%, respectively, had ≥50% improvement in CLASI activity score. No deaths, malignancies, opportunistic infections, or tuberculosis cases occurred. Safety events were consistent with the known ustekinumab safety profile. CONCLUSION In the 46 patients who entered the voluntary extension of this phase 2 study, clinical benefit in global and organ-specific SLE-activity measures was observed with ustekinumab through 2years with no new or unexpected safety findings. clinicaltrials.gov: NCT02349061.
Collapse
Affiliation(s)
- Ronald F van Vollenhoven
- Amsterdam University Medical Centers, Amsterdam, Netherlands; University of California Los Angeles, CA, USA; Harvard Medical School, Beth Israel Deaconess Medical Center Boston, MA, USA; 4AMPEL BioSolutions, LLC, Charlottesville, VA, USA; 5Janssen Research & Development, LLC, Spring House, PA, USA; 6Janssen Global Services, LLC, Horsham, PA, USA. Funding: This study was funded by Janssen Research & Development, LLC. Keywords: systemic lupus erythematosus; ustekinumab; interleukin-12; interleukin-23 Running head: Ustekinumab in SLE through 2 years. Conflicts of interest: RFvV has received consulting fees, speaking fees, and/or honoraria from AbbVie, AstraZeneca, Biotest, Bristol-Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Janssen, Medac, Merck, Novartis, Pfizer, Roche, and UCB and research support from AbbVie, Arthrogen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Pfizer, and UCB. BHH has received consulting fees, speaking fees, and/or honoraria from Aurinia, GSK and UCB. GCT has received consulting fees from A2 Therapeutics and research support from Janssen. PL has received consulting fees from Janssen. RMG, KF, KHL, MC*, SR, ZY, CSK, and QZ are or were employees of Janssen Research & Development, LLC when this work was performed and own stock in Johnson & Johnson, of which Janssen Research & Development, LLC, is a wholly-owned subsidiary. *Dr. Marc Chevrier contributed to the development of this manuscript but passed away prior to submission. The authors agreed that Dr. Chevrier qualified as an author. PB is an employee of Janssen Global Services, LLC, and owns stock in Johnson & Johnson, of which Janssen Global Services, LLC, is a wholly-owned subsidiary. Corresponding author: Ronald F. van Vollenhoven, MD, PhD, Amsterdam University Medical Centers, University of Amsterdam, PO Box 7057, 1007 MB Amsterdam, Netherlands.
| | - Bevra H Hahn
- Amsterdam University Medical Centers, Amsterdam, Netherlands; University of California Los Angeles, CA, USA; Harvard Medical School, Beth Israel Deaconess Medical Center Boston, MA, USA; 4AMPEL BioSolutions, LLC, Charlottesville, VA, USA; 5Janssen Research & Development, LLC, Spring House, PA, USA; 6Janssen Global Services, LLC, Horsham, PA, USA. Funding: This study was funded by Janssen Research & Development, LLC. Keywords: systemic lupus erythematosus; ustekinumab; interleukin-12; interleukin-23 Running head: Ustekinumab in SLE through 2 years. Conflicts of interest: RFvV has received consulting fees, speaking fees, and/or honoraria from AbbVie, AstraZeneca, Biotest, Bristol-Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Janssen, Medac, Merck, Novartis, Pfizer, Roche, and UCB and research support from AbbVie, Arthrogen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Pfizer, and UCB. BHH has received consulting fees, speaking fees, and/or honoraria from Aurinia, GSK and UCB. GCT has received consulting fees from A2 Therapeutics and research support from Janssen. PL has received consulting fees from Janssen. RMG, KF, KHL, MC*, SR, ZY, CSK, and QZ are or were employees of Janssen Research & Development, LLC when this work was performed and own stock in Johnson & Johnson, of which Janssen Research & Development, LLC, is a wholly-owned subsidiary. *Dr. Marc Chevrier contributed to the development of this manuscript but passed away prior to submission. The authors agreed that Dr. Chevrier qualified as an author. PB is an employee of Janssen Global Services, LLC, and owns stock in Johnson & Johnson, of which Janssen Global Services, LLC, is a wholly-owned subsidiary. Corresponding author: Ronald F. van Vollenhoven, MD, PhD, Amsterdam University Medical Centers, University of Amsterdam, PO Box 7057, 1007 MB Amsterdam, Netherlands.
| | - George C Tsokos
- Amsterdam University Medical Centers, Amsterdam, Netherlands; University of California Los Angeles, CA, USA; Harvard Medical School, Beth Israel Deaconess Medical Center Boston, MA, USA; 4AMPEL BioSolutions, LLC, Charlottesville, VA, USA; 5Janssen Research & Development, LLC, Spring House, PA, USA; 6Janssen Global Services, LLC, Horsham, PA, USA. Funding: This study was funded by Janssen Research & Development, LLC. Keywords: systemic lupus erythematosus; ustekinumab; interleukin-12; interleukin-23 Running head: Ustekinumab in SLE through 2 years. Conflicts of interest: RFvV has received consulting fees, speaking fees, and/or honoraria from AbbVie, AstraZeneca, Biotest, Bristol-Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Janssen, Medac, Merck, Novartis, Pfizer, Roche, and UCB and research support from AbbVie, Arthrogen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Pfizer, and UCB. BHH has received consulting fees, speaking fees, and/or honoraria from Aurinia, GSK and UCB. GCT has received consulting fees from A2 Therapeutics and research support from Janssen. PL has received consulting fees from Janssen. RMG, KF, KHL, MC*, SR, ZY, CSK, and QZ are or were employees of Janssen Research & Development, LLC when this work was performed and own stock in Johnson & Johnson, of which Janssen Research & Development, LLC, is a wholly-owned subsidiary. *Dr. Marc Chevrier contributed to the development of this manuscript but passed away prior to submission. The authors agreed that Dr. Chevrier qualified as an author. PB is an employee of Janssen Global Services, LLC, and owns stock in Johnson & Johnson, of which Janssen Global Services, LLC, is a wholly-owned subsidiary. Corresponding author: Ronald F. van Vollenhoven, MD, PhD, Amsterdam University Medical Centers, University of Amsterdam, PO Box 7057, 1007 MB Amsterdam, Netherlands.
| | - Peter Lipsky
- Amsterdam University Medical Centers, Amsterdam, Netherlands; University of California Los Angeles, CA, USA; Harvard Medical School, Beth Israel Deaconess Medical Center Boston, MA, USA; 4AMPEL BioSolutions, LLC, Charlottesville, VA, USA; 5Janssen Research & Development, LLC, Spring House, PA, USA; 6Janssen Global Services, LLC, Horsham, PA, USA. Funding: This study was funded by Janssen Research & Development, LLC. Keywords: systemic lupus erythematosus; ustekinumab; interleukin-12; interleukin-23 Running head: Ustekinumab in SLE through 2 years. Conflicts of interest: RFvV has received consulting fees, speaking fees, and/or honoraria from AbbVie, AstraZeneca, Biotest, Bristol-Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Janssen, Medac, Merck, Novartis, Pfizer, Roche, and UCB and research support from AbbVie, Arthrogen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Pfizer, and UCB. BHH has received consulting fees, speaking fees, and/or honoraria from Aurinia, GSK and UCB. GCT has received consulting fees from A2 Therapeutics and research support from Janssen. PL has received consulting fees from Janssen. RMG, KF, KHL, MC*, SR, ZY, CSK, and QZ are or were employees of Janssen Research & Development, LLC when this work was performed and own stock in Johnson & Johnson, of which Janssen Research & Development, LLC, is a wholly-owned subsidiary. *Dr. Marc Chevrier contributed to the development of this manuscript but passed away prior to submission. The authors agreed that Dr. Chevrier qualified as an author. PB is an employee of Janssen Global Services, LLC, and owns stock in Johnson & Johnson, of which Janssen Global Services, LLC, is a wholly-owned subsidiary. Corresponding author: Ronald F. van Vollenhoven, MD, PhD, Amsterdam University Medical Centers, University of Amsterdam, PO Box 7057, 1007 MB Amsterdam, Netherlands.
| | - Robert M Gordon
- Amsterdam University Medical Centers, Amsterdam, Netherlands; University of California Los Angeles, CA, USA; Harvard Medical School, Beth Israel Deaconess Medical Center Boston, MA, USA; 4AMPEL BioSolutions, LLC, Charlottesville, VA, USA; 5Janssen Research & Development, LLC, Spring House, PA, USA; 6Janssen Global Services, LLC, Horsham, PA, USA. Funding: This study was funded by Janssen Research & Development, LLC. Keywords: systemic lupus erythematosus; ustekinumab; interleukin-12; interleukin-23 Running head: Ustekinumab in SLE through 2 years. Conflicts of interest: RFvV has received consulting fees, speaking fees, and/or honoraria from AbbVie, AstraZeneca, Biotest, Bristol-Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Janssen, Medac, Merck, Novartis, Pfizer, Roche, and UCB and research support from AbbVie, Arthrogen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Pfizer, and UCB. BHH has received consulting fees, speaking fees, and/or honoraria from Aurinia, GSK and UCB. GCT has received consulting fees from A2 Therapeutics and research support from Janssen. PL has received consulting fees from Janssen. RMG, KF, KHL, MC*, SR, ZY, CSK, and QZ are or were employees of Janssen Research & Development, LLC when this work was performed and own stock in Johnson & Johnson, of which Janssen Research & Development, LLC, is a wholly-owned subsidiary. *Dr. Marc Chevrier contributed to the development of this manuscript but passed away prior to submission. The authors agreed that Dr. Chevrier qualified as an author. PB is an employee of Janssen Global Services, LLC, and owns stock in Johnson & Johnson, of which Janssen Global Services, LLC, is a wholly-owned subsidiary. Corresponding author: Ronald F. van Vollenhoven, MD, PhD, Amsterdam University Medical Centers, University of Amsterdam, PO Box 7057, 1007 MB Amsterdam, Netherlands.
| | - Kaiyin Fei
- Amsterdam University Medical Centers, Amsterdam, Netherlands; University of California Los Angeles, CA, USA; Harvard Medical School, Beth Israel Deaconess Medical Center Boston, MA, USA; 4AMPEL BioSolutions, LLC, Charlottesville, VA, USA; 5Janssen Research & Development, LLC, Spring House, PA, USA; 6Janssen Global Services, LLC, Horsham, PA, USA. Funding: This study was funded by Janssen Research & Development, LLC. Keywords: systemic lupus erythematosus; ustekinumab; interleukin-12; interleukin-23 Running head: Ustekinumab in SLE through 2 years. Conflicts of interest: RFvV has received consulting fees, speaking fees, and/or honoraria from AbbVie, AstraZeneca, Biotest, Bristol-Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Janssen, Medac, Merck, Novartis, Pfizer, Roche, and UCB and research support from AbbVie, Arthrogen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Pfizer, and UCB. BHH has received consulting fees, speaking fees, and/or honoraria from Aurinia, GSK and UCB. GCT has received consulting fees from A2 Therapeutics and research support from Janssen. PL has received consulting fees from Janssen. RMG, KF, KHL, MC*, SR, ZY, CSK, and QZ are or were employees of Janssen Research & Development, LLC when this work was performed and own stock in Johnson & Johnson, of which Janssen Research & Development, LLC, is a wholly-owned subsidiary. *Dr. Marc Chevrier contributed to the development of this manuscript but passed away prior to submission. The authors agreed that Dr. Chevrier qualified as an author. PB is an employee of Janssen Global Services, LLC, and owns stock in Johnson & Johnson, of which Janssen Global Services, LLC, is a wholly-owned subsidiary. Corresponding author: Ronald F. van Vollenhoven, MD, PhD, Amsterdam University Medical Centers, University of Amsterdam, PO Box 7057, 1007 MB Amsterdam, Netherlands.
| | - Kim Hung Lo
- Amsterdam University Medical Centers, Amsterdam, Netherlands; University of California Los Angeles, CA, USA; Harvard Medical School, Beth Israel Deaconess Medical Center Boston, MA, USA; 4AMPEL BioSolutions, LLC, Charlottesville, VA, USA; 5Janssen Research & Development, LLC, Spring House, PA, USA; 6Janssen Global Services, LLC, Horsham, PA, USA. Funding: This study was funded by Janssen Research & Development, LLC. Keywords: systemic lupus erythematosus; ustekinumab; interleukin-12; interleukin-23 Running head: Ustekinumab in SLE through 2 years. Conflicts of interest: RFvV has received consulting fees, speaking fees, and/or honoraria from AbbVie, AstraZeneca, Biotest, Bristol-Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Janssen, Medac, Merck, Novartis, Pfizer, Roche, and UCB and research support from AbbVie, Arthrogen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Pfizer, and UCB. BHH has received consulting fees, speaking fees, and/or honoraria from Aurinia, GSK and UCB. GCT has received consulting fees from A2 Therapeutics and research support from Janssen. PL has received consulting fees from Janssen. RMG, KF, KHL, MC*, SR, ZY, CSK, and QZ are or were employees of Janssen Research & Development, LLC when this work was performed and own stock in Johnson & Johnson, of which Janssen Research & Development, LLC, is a wholly-owned subsidiary. *Dr. Marc Chevrier contributed to the development of this manuscript but passed away prior to submission. The authors agreed that Dr. Chevrier qualified as an author. PB is an employee of Janssen Global Services, LLC, and owns stock in Johnson & Johnson, of which Janssen Global Services, LLC, is a wholly-owned subsidiary. Corresponding author: Ronald F. van Vollenhoven, MD, PhD, Amsterdam University Medical Centers, University of Amsterdam, PO Box 7057, 1007 MB Amsterdam, Netherlands.
| | - Marc Chevrier
- Amsterdam University Medical Centers, Amsterdam, Netherlands; University of California Los Angeles, CA, USA; Harvard Medical School, Beth Israel Deaconess Medical Center Boston, MA, USA; 4AMPEL BioSolutions, LLC, Charlottesville, VA, USA; 5Janssen Research & Development, LLC, Spring House, PA, USA; 6Janssen Global Services, LLC, Horsham, PA, USA. Funding: This study was funded by Janssen Research & Development, LLC. Keywords: systemic lupus erythematosus; ustekinumab; interleukin-12; interleukin-23 Running head: Ustekinumab in SLE through 2 years. Conflicts of interest: RFvV has received consulting fees, speaking fees, and/or honoraria from AbbVie, AstraZeneca, Biotest, Bristol-Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Janssen, Medac, Merck, Novartis, Pfizer, Roche, and UCB and research support from AbbVie, Arthrogen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Pfizer, and UCB. BHH has received consulting fees, speaking fees, and/or honoraria from Aurinia, GSK and UCB. GCT has received consulting fees from A2 Therapeutics and research support from Janssen. PL has received consulting fees from Janssen. RMG, KF, KHL, MC*, SR, ZY, CSK, and QZ are or were employees of Janssen Research & Development, LLC when this work was performed and own stock in Johnson & Johnson, of which Janssen Research & Development, LLC, is a wholly-owned subsidiary. *Dr. Marc Chevrier contributed to the development of this manuscript but passed away prior to submission. The authors agreed that Dr. Chevrier qualified as an author. PB is an employee of Janssen Global Services, LLC, and owns stock in Johnson & Johnson, of which Janssen Global Services, LLC, is a wholly-owned subsidiary. Corresponding author: Ronald F. van Vollenhoven, MD, PhD, Amsterdam University Medical Centers, University of Amsterdam, PO Box 7057, 1007 MB Amsterdam, Netherlands.
| | - Shawn Rose
- Amsterdam University Medical Centers, Amsterdam, Netherlands; University of California Los Angeles, CA, USA; Harvard Medical School, Beth Israel Deaconess Medical Center Boston, MA, USA; 4AMPEL BioSolutions, LLC, Charlottesville, VA, USA; 5Janssen Research & Development, LLC, Spring House, PA, USA; 6Janssen Global Services, LLC, Horsham, PA, USA. Funding: This study was funded by Janssen Research & Development, LLC. Keywords: systemic lupus erythematosus; ustekinumab; interleukin-12; interleukin-23 Running head: Ustekinumab in SLE through 2 years. Conflicts of interest: RFvV has received consulting fees, speaking fees, and/or honoraria from AbbVie, AstraZeneca, Biotest, Bristol-Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Janssen, Medac, Merck, Novartis, Pfizer, Roche, and UCB and research support from AbbVie, Arthrogen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Pfizer, and UCB. BHH has received consulting fees, speaking fees, and/or honoraria from Aurinia, GSK and UCB. GCT has received consulting fees from A2 Therapeutics and research support from Janssen. PL has received consulting fees from Janssen. RMG, KF, KHL, MC*, SR, ZY, CSK, and QZ are or were employees of Janssen Research & Development, LLC when this work was performed and own stock in Johnson & Johnson, of which Janssen Research & Development, LLC, is a wholly-owned subsidiary. *Dr. Marc Chevrier contributed to the development of this manuscript but passed away prior to submission. The authors agreed that Dr. Chevrier qualified as an author. PB is an employee of Janssen Global Services, LLC, and owns stock in Johnson & Johnson, of which Janssen Global Services, LLC, is a wholly-owned subsidiary. Corresponding author: Ronald F. van Vollenhoven, MD, PhD, Amsterdam University Medical Centers, University of Amsterdam, PO Box 7057, 1007 MB Amsterdam, Netherlands.
| | - Pamela Berry
- Amsterdam University Medical Centers, Amsterdam, Netherlands; University of California Los Angeles, CA, USA; Harvard Medical School, Beth Israel Deaconess Medical Center Boston, MA, USA; 4AMPEL BioSolutions, LLC, Charlottesville, VA, USA; 5Janssen Research & Development, LLC, Spring House, PA, USA; 6Janssen Global Services, LLC, Horsham, PA, USA. Funding: This study was funded by Janssen Research & Development, LLC. Keywords: systemic lupus erythematosus; ustekinumab; interleukin-12; interleukin-23 Running head: Ustekinumab in SLE through 2 years. Conflicts of interest: RFvV has received consulting fees, speaking fees, and/or honoraria from AbbVie, AstraZeneca, Biotest, Bristol-Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Janssen, Medac, Merck, Novartis, Pfizer, Roche, and UCB and research support from AbbVie, Arthrogen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Pfizer, and UCB. BHH has received consulting fees, speaking fees, and/or honoraria from Aurinia, GSK and UCB. GCT has received consulting fees from A2 Therapeutics and research support from Janssen. PL has received consulting fees from Janssen. RMG, KF, KHL, MC*, SR, ZY, CSK, and QZ are or were employees of Janssen Research & Development, LLC when this work was performed and own stock in Johnson & Johnson, of which Janssen Research & Development, LLC, is a wholly-owned subsidiary. *Dr. Marc Chevrier contributed to the development of this manuscript but passed away prior to submission. The authors agreed that Dr. Chevrier qualified as an author. PB is an employee of Janssen Global Services, LLC, and owns stock in Johnson & Johnson, of which Janssen Global Services, LLC, is a wholly-owned subsidiary. Corresponding author: Ronald F. van Vollenhoven, MD, PhD, Amsterdam University Medical Centers, University of Amsterdam, PO Box 7057, 1007 MB Amsterdam, Netherlands.
| | - Zhenling Yao
- Amsterdam University Medical Centers, Amsterdam, Netherlands; University of California Los Angeles, CA, USA; Harvard Medical School, Beth Israel Deaconess Medical Center Boston, MA, USA; 4AMPEL BioSolutions, LLC, Charlottesville, VA, USA; 5Janssen Research & Development, LLC, Spring House, PA, USA; 6Janssen Global Services, LLC, Horsham, PA, USA. Funding: This study was funded by Janssen Research & Development, LLC. Keywords: systemic lupus erythematosus; ustekinumab; interleukin-12; interleukin-23 Running head: Ustekinumab in SLE through 2 years. Conflicts of interest: RFvV has received consulting fees, speaking fees, and/or honoraria from AbbVie, AstraZeneca, Biotest, Bristol-Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Janssen, Medac, Merck, Novartis, Pfizer, Roche, and UCB and research support from AbbVie, Arthrogen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Pfizer, and UCB. BHH has received consulting fees, speaking fees, and/or honoraria from Aurinia, GSK and UCB. GCT has received consulting fees from A2 Therapeutics and research support from Janssen. PL has received consulting fees from Janssen. RMG, KF, KHL, MC*, SR, ZY, CSK, and QZ are or were employees of Janssen Research & Development, LLC when this work was performed and own stock in Johnson & Johnson, of which Janssen Research & Development, LLC, is a wholly-owned subsidiary. *Dr. Marc Chevrier contributed to the development of this manuscript but passed away prior to submission. The authors agreed that Dr. Chevrier qualified as an author. PB is an employee of Janssen Global Services, LLC, and owns stock in Johnson & Johnson, of which Janssen Global Services, LLC, is a wholly-owned subsidiary. Corresponding author: Ronald F. van Vollenhoven, MD, PhD, Amsterdam University Medical Centers, University of Amsterdam, PO Box 7057, 1007 MB Amsterdam, Netherlands.
| | - Chetan S Karyekar
- Amsterdam University Medical Centers, Amsterdam, Netherlands; University of California Los Angeles, CA, USA; Harvard Medical School, Beth Israel Deaconess Medical Center Boston, MA, USA; 4AMPEL BioSolutions, LLC, Charlottesville, VA, USA; 5Janssen Research & Development, LLC, Spring House, PA, USA; 6Janssen Global Services, LLC, Horsham, PA, USA. Funding: This study was funded by Janssen Research & Development, LLC. Keywords: systemic lupus erythematosus; ustekinumab; interleukin-12; interleukin-23 Running head: Ustekinumab in SLE through 2 years. Conflicts of interest: RFvV has received consulting fees, speaking fees, and/or honoraria from AbbVie, AstraZeneca, Biotest, Bristol-Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Janssen, Medac, Merck, Novartis, Pfizer, Roche, and UCB and research support from AbbVie, Arthrogen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Pfizer, and UCB. BHH has received consulting fees, speaking fees, and/or honoraria from Aurinia, GSK and UCB. GCT has received consulting fees from A2 Therapeutics and research support from Janssen. PL has received consulting fees from Janssen. RMG, KF, KHL, MC*, SR, ZY, CSK, and QZ are or were employees of Janssen Research & Development, LLC when this work was performed and own stock in Johnson & Johnson, of which Janssen Research & Development, LLC, is a wholly-owned subsidiary. *Dr. Marc Chevrier contributed to the development of this manuscript but passed away prior to submission. The authors agreed that Dr. Chevrier qualified as an author. PB is an employee of Janssen Global Services, LLC, and owns stock in Johnson & Johnson, of which Janssen Global Services, LLC, is a wholly-owned subsidiary. Corresponding author: Ronald F. van Vollenhoven, MD, PhD, Amsterdam University Medical Centers, University of Amsterdam, PO Box 7057, 1007 MB Amsterdam, Netherlands.
| | - Qing Zuraw
- Amsterdam University Medical Centers, Amsterdam, Netherlands; University of California Los Angeles, CA, USA; Harvard Medical School, Beth Israel Deaconess Medical Center Boston, MA, USA; 4AMPEL BioSolutions, LLC, Charlottesville, VA, USA; 5Janssen Research & Development, LLC, Spring House, PA, USA; 6Janssen Global Services, LLC, Horsham, PA, USA. Funding: This study was funded by Janssen Research & Development, LLC. Keywords: systemic lupus erythematosus; ustekinumab; interleukin-12; interleukin-23 Running head: Ustekinumab in SLE through 2 years. Conflicts of interest: RFvV has received consulting fees, speaking fees, and/or honoraria from AbbVie, AstraZeneca, Biotest, Bristol-Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Janssen, Medac, Merck, Novartis, Pfizer, Roche, and UCB and research support from AbbVie, Arthrogen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Pfizer, and UCB. BHH has received consulting fees, speaking fees, and/or honoraria from Aurinia, GSK and UCB. GCT has received consulting fees from A2 Therapeutics and research support from Janssen. PL has received consulting fees from Janssen. RMG, KF, KHL, MC*, SR, ZY, CSK, and QZ are or were employees of Janssen Research & Development, LLC when this work was performed and own stock in Johnson & Johnson, of which Janssen Research & Development, LLC, is a wholly-owned subsidiary. *Dr. Marc Chevrier contributed to the development of this manuscript but passed away prior to submission. The authors agreed that Dr. Chevrier qualified as an author. PB is an employee of Janssen Global Services, LLC, and owns stock in Johnson & Johnson, of which Janssen Global Services, LLC, is a wholly-owned subsidiary. Corresponding author: Ronald F. van Vollenhoven, MD, PhD, Amsterdam University Medical Centers, University of Amsterdam, PO Box 7057, 1007 MB Amsterdam, Netherlands.
| |
Collapse
|
45
|
Rahman P, Ritchlin CT, Helliwell PS, Boehncke WH, Mease PJ, Gottlieb AB, Kafka S, Kollmeier AP, Hsia EC, Xu XL, Shawi M, Sheng S, Agarwal P, Zhou B, Ramachandran P, Zhuang Y, McInnes IB. Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis. J Rheumatol 2021; 48:1815-1823. [PMID: 33934076 DOI: 10.3899/jrheum.201532] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/20/2021] [Indexed: 10/21/2022]
Abstract
OBJECTIVE Evaluate the safety of guselkumab (monoclonal antibody targeting interleukin [IL]-23p19) in patients with psoriatic arthritis (PsA) through 1 year (1Y) of the phase III DISCOVER-1 and DISCOVER-2 trials. METHODS Patients with active PsA (n = 1120; biologic-naïve except 118 patients treated with tumor necrosis factor inhibitors in DISCOVER-1) were randomized to subcutaneous guselkumab 100 mg every 4 weeks (Q4W) or at Week 0, Week 4, then every 8 weeks (Q8W); or placebo. At Week 24, patients in the placebo group switched to guselkumab 100 mg Q4W. Treatment continued through 1Y and 2 years for DISCOVER-1 and DISCOVER-2, respectively. In this pooled analysis, patients with ≥ 1 adverse event (AE) through 1Y were standardized for 100 patient-years [100 PYs] of follow-up. RESULTS Through Week 24, adverse events (AEs) were consistent between patients treated with placebo and guselkumab (Q4W + Q8W). AEs were 142.8/100 PYs and 150.6/100 PYs, serious AEs were 7.1/100 PYs and 4.4/100 PYs, and AEs leading to study agent discontinuation were 4.1/100 PYs and 3.8/100 PYs, respectively. Through 1Y in patients treated with guselkumab, no uveitis, active tuberculosis, opportunistic infections, or inflammatory bowel disease were observed, and low rates of malignancy and major adverse cardiovascular (CV) events were observed. Injection-site reactions occurred in 1.7%, and antibodies to guselkumab in 4.5% of patients treated with guselkumab through 1Y; the vast majority of antibodies to guselkumab were nonneutralizing. Serum hepatic transaminase elevations (more common with Q4W than Q8W dosing) and decreased neutrophil counts were generally mild, transient, and did not require treatment discontinuation, with minimal change from Week 24 to 1Y. CONCLUSION Guselkumab 100 mg Q4W and Q8W were well tolerated in patients with PsA, with no new safety concerns through 1Y of the phase III DISCOVER trials. Guselkumab safety through 1Y in patients with PsA is consistent with that established in patients with psoriasis who were treated with guselkumab.
Collapse
Affiliation(s)
- Proton Rahman
- This study was sponsored by Janssen Research & Development. P. Rahman, MD, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; C.T. Ritchlin, MD, MPH, University of Rochester, Rochester, New York, USA; P.S. Helliwell, PhD, University of Leeds, Leeds, UK; W.H. Boehncke, MD, Geneva University Hospitals, Geneva, Switzerland; P.J. Mease, MD, Swedish Medical Center/Providence St Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A.B. Gottlieb, MD, PhD, Icahn Medical School at Mount Sinai, New York, New York, USA; S. Kafka, MD, Janssen Scientific Affairs, Horsham, Pennsylvania, USA; A.P. Kollmeier, MD, X.L. Xu, PhD, Janssen Research & Development, San Diego, California, USA; E.C. Hsia, MD, Janssen Research & Development, Spring House, Pennsylvania, USA, and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; M. Shawi, PhD, Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, Pennsylvania, USA; S. Sheng, PhD, P. Agarwal, PhD, B. Zhou, PhD, P. Ramachandran, MD, MPH, Y. Zhuang, PhD, Janssen Research & Development, Spring House, Pennsylvania, USA; I.B. McInnes, MD, PhD, University of Glasgow, Glasgow, UK. CTR has received research support from AbbVie, Amgen, and UCB, and consultant fees from AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received research support from Janssen and Novartis; consultant fees from Abbott, AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB; and speakers bureau support from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. PSH has received consulting fees from Eli Lilly and fees for educational services from Amgen, Janssen, Novartis, and Pfizer. WHB has received research support from Pfizer and consulting fees and speaker bureau support from AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Novartis, and UCB. IBM has received research support from AstraZeneca, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB, and consultant fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Gilead, Janssen, Novartis, and UCB. ABG has received research support from Boehringer Ingelheim, Incyte, Janssen, Novartis, Sun Pharmaceutical Industries, UCB, and XBiotech; honoraria from Amgen, BMS, Celgene, Janssen, LEO Pharma, Novartis, and UCB Pharma; consultant fees from AnaptysBio, Avotres, Boehringer Ingelheim, Incyte, Lilly ICOS, Novartis, Pfizer, and Sun Pharmaceutical Industries; and stock options from XBiotech. PJM has received research support, consulting fees, and speaker bureau support from AbbVie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB. SK was an employee of Janssen Scientific Affairs at the time this work was performed; APK, ECH, XLX, SS, PA, BZ, PR, and YZ are employees of Janssen Research & Development; and MS is an employee of Janssen Global Services-these authors own stock or stock options in Johnson & Johnson. Address correspondence to Dr. P. Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's, NL A1C 5B8, Canada. . Accepted for publication April 20, 2021
| | - Christopher T Ritchlin
- This study was sponsored by Janssen Research & Development. P. Rahman, MD, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; C.T. Ritchlin, MD, MPH, University of Rochester, Rochester, New York, USA; P.S. Helliwell, PhD, University of Leeds, Leeds, UK; W.H. Boehncke, MD, Geneva University Hospitals, Geneva, Switzerland; P.J. Mease, MD, Swedish Medical Center/Providence St Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A.B. Gottlieb, MD, PhD, Icahn Medical School at Mount Sinai, New York, New York, USA; S. Kafka, MD, Janssen Scientific Affairs, Horsham, Pennsylvania, USA; A.P. Kollmeier, MD, X.L. Xu, PhD, Janssen Research & Development, San Diego, California, USA; E.C. Hsia, MD, Janssen Research & Development, Spring House, Pennsylvania, USA, and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; M. Shawi, PhD, Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, Pennsylvania, USA; S. Sheng, PhD, P. Agarwal, PhD, B. Zhou, PhD, P. Ramachandran, MD, MPH, Y. Zhuang, PhD, Janssen Research & Development, Spring House, Pennsylvania, USA; I.B. McInnes, MD, PhD, University of Glasgow, Glasgow, UK. CTR has received research support from AbbVie, Amgen, and UCB, and consultant fees from AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received research support from Janssen and Novartis; consultant fees from Abbott, AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB; and speakers bureau support from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. PSH has received consulting fees from Eli Lilly and fees for educational services from Amgen, Janssen, Novartis, and Pfizer. WHB has received research support from Pfizer and consulting fees and speaker bureau support from AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Novartis, and UCB. IBM has received research support from AstraZeneca, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB, and consultant fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Gilead, Janssen, Novartis, and UCB. ABG has received research support from Boehringer Ingelheim, Incyte, Janssen, Novartis, Sun Pharmaceutical Industries, UCB, and XBiotech; honoraria from Amgen, BMS, Celgene, Janssen, LEO Pharma, Novartis, and UCB Pharma; consultant fees from AnaptysBio, Avotres, Boehringer Ingelheim, Incyte, Lilly ICOS, Novartis, Pfizer, and Sun Pharmaceutical Industries; and stock options from XBiotech. PJM has received research support, consulting fees, and speaker bureau support from AbbVie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB. SK was an employee of Janssen Scientific Affairs at the time this work was performed; APK, ECH, XLX, SS, PA, BZ, PR, and YZ are employees of Janssen Research & Development; and MS is an employee of Janssen Global Services-these authors own stock or stock options in Johnson & Johnson. Address correspondence to Dr. P. Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's, NL A1C 5B8, Canada. . Accepted for publication April 20, 2021
| | - Philip S Helliwell
- This study was sponsored by Janssen Research & Development. P. Rahman, MD, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; C.T. Ritchlin, MD, MPH, University of Rochester, Rochester, New York, USA; P.S. Helliwell, PhD, University of Leeds, Leeds, UK; W.H. Boehncke, MD, Geneva University Hospitals, Geneva, Switzerland; P.J. Mease, MD, Swedish Medical Center/Providence St Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A.B. Gottlieb, MD, PhD, Icahn Medical School at Mount Sinai, New York, New York, USA; S. Kafka, MD, Janssen Scientific Affairs, Horsham, Pennsylvania, USA; A.P. Kollmeier, MD, X.L. Xu, PhD, Janssen Research & Development, San Diego, California, USA; E.C. Hsia, MD, Janssen Research & Development, Spring House, Pennsylvania, USA, and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; M. Shawi, PhD, Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, Pennsylvania, USA; S. Sheng, PhD, P. Agarwal, PhD, B. Zhou, PhD, P. Ramachandran, MD, MPH, Y. Zhuang, PhD, Janssen Research & Development, Spring House, Pennsylvania, USA; I.B. McInnes, MD, PhD, University of Glasgow, Glasgow, UK. CTR has received research support from AbbVie, Amgen, and UCB, and consultant fees from AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received research support from Janssen and Novartis; consultant fees from Abbott, AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB; and speakers bureau support from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. PSH has received consulting fees from Eli Lilly and fees for educational services from Amgen, Janssen, Novartis, and Pfizer. WHB has received research support from Pfizer and consulting fees and speaker bureau support from AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Novartis, and UCB. IBM has received research support from AstraZeneca, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB, and consultant fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Gilead, Janssen, Novartis, and UCB. ABG has received research support from Boehringer Ingelheim, Incyte, Janssen, Novartis, Sun Pharmaceutical Industries, UCB, and XBiotech; honoraria from Amgen, BMS, Celgene, Janssen, LEO Pharma, Novartis, and UCB Pharma; consultant fees from AnaptysBio, Avotres, Boehringer Ingelheim, Incyte, Lilly ICOS, Novartis, Pfizer, and Sun Pharmaceutical Industries; and stock options from XBiotech. PJM has received research support, consulting fees, and speaker bureau support from AbbVie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB. SK was an employee of Janssen Scientific Affairs at the time this work was performed; APK, ECH, XLX, SS, PA, BZ, PR, and YZ are employees of Janssen Research & Development; and MS is an employee of Janssen Global Services-these authors own stock or stock options in Johnson & Johnson. Address correspondence to Dr. P. Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's, NL A1C 5B8, Canada. . Accepted for publication April 20, 2021
| | - Wolf-Henning Boehncke
- This study was sponsored by Janssen Research & Development. P. Rahman, MD, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; C.T. Ritchlin, MD, MPH, University of Rochester, Rochester, New York, USA; P.S. Helliwell, PhD, University of Leeds, Leeds, UK; W.H. Boehncke, MD, Geneva University Hospitals, Geneva, Switzerland; P.J. Mease, MD, Swedish Medical Center/Providence St Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A.B. Gottlieb, MD, PhD, Icahn Medical School at Mount Sinai, New York, New York, USA; S. Kafka, MD, Janssen Scientific Affairs, Horsham, Pennsylvania, USA; A.P. Kollmeier, MD, X.L. Xu, PhD, Janssen Research & Development, San Diego, California, USA; E.C. Hsia, MD, Janssen Research & Development, Spring House, Pennsylvania, USA, and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; M. Shawi, PhD, Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, Pennsylvania, USA; S. Sheng, PhD, P. Agarwal, PhD, B. Zhou, PhD, P. Ramachandran, MD, MPH, Y. Zhuang, PhD, Janssen Research & Development, Spring House, Pennsylvania, USA; I.B. McInnes, MD, PhD, University of Glasgow, Glasgow, UK. CTR has received research support from AbbVie, Amgen, and UCB, and consultant fees from AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received research support from Janssen and Novartis; consultant fees from Abbott, AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB; and speakers bureau support from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. PSH has received consulting fees from Eli Lilly and fees for educational services from Amgen, Janssen, Novartis, and Pfizer. WHB has received research support from Pfizer and consulting fees and speaker bureau support from AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Novartis, and UCB. IBM has received research support from AstraZeneca, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB, and consultant fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Gilead, Janssen, Novartis, and UCB. ABG has received research support from Boehringer Ingelheim, Incyte, Janssen, Novartis, Sun Pharmaceutical Industries, UCB, and XBiotech; honoraria from Amgen, BMS, Celgene, Janssen, LEO Pharma, Novartis, and UCB Pharma; consultant fees from AnaptysBio, Avotres, Boehringer Ingelheim, Incyte, Lilly ICOS, Novartis, Pfizer, and Sun Pharmaceutical Industries; and stock options from XBiotech. PJM has received research support, consulting fees, and speaker bureau support from AbbVie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB. SK was an employee of Janssen Scientific Affairs at the time this work was performed; APK, ECH, XLX, SS, PA, BZ, PR, and YZ are employees of Janssen Research & Development; and MS is an employee of Janssen Global Services-these authors own stock or stock options in Johnson & Johnson. Address correspondence to Dr. P. Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's, NL A1C 5B8, Canada. . Accepted for publication April 20, 2021
| | - Philip J Mease
- This study was sponsored by Janssen Research & Development. P. Rahman, MD, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; C.T. Ritchlin, MD, MPH, University of Rochester, Rochester, New York, USA; P.S. Helliwell, PhD, University of Leeds, Leeds, UK; W.H. Boehncke, MD, Geneva University Hospitals, Geneva, Switzerland; P.J. Mease, MD, Swedish Medical Center/Providence St Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A.B. Gottlieb, MD, PhD, Icahn Medical School at Mount Sinai, New York, New York, USA; S. Kafka, MD, Janssen Scientific Affairs, Horsham, Pennsylvania, USA; A.P. Kollmeier, MD, X.L. Xu, PhD, Janssen Research & Development, San Diego, California, USA; E.C. Hsia, MD, Janssen Research & Development, Spring House, Pennsylvania, USA, and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; M. Shawi, PhD, Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, Pennsylvania, USA; S. Sheng, PhD, P. Agarwal, PhD, B. Zhou, PhD, P. Ramachandran, MD, MPH, Y. Zhuang, PhD, Janssen Research & Development, Spring House, Pennsylvania, USA; I.B. McInnes, MD, PhD, University of Glasgow, Glasgow, UK. CTR has received research support from AbbVie, Amgen, and UCB, and consultant fees from AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received research support from Janssen and Novartis; consultant fees from Abbott, AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB; and speakers bureau support from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. PSH has received consulting fees from Eli Lilly and fees for educational services from Amgen, Janssen, Novartis, and Pfizer. WHB has received research support from Pfizer and consulting fees and speaker bureau support from AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Novartis, and UCB. IBM has received research support from AstraZeneca, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB, and consultant fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Gilead, Janssen, Novartis, and UCB. ABG has received research support from Boehringer Ingelheim, Incyte, Janssen, Novartis, Sun Pharmaceutical Industries, UCB, and XBiotech; honoraria from Amgen, BMS, Celgene, Janssen, LEO Pharma, Novartis, and UCB Pharma; consultant fees from AnaptysBio, Avotres, Boehringer Ingelheim, Incyte, Lilly ICOS, Novartis, Pfizer, and Sun Pharmaceutical Industries; and stock options from XBiotech. PJM has received research support, consulting fees, and speaker bureau support from AbbVie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB. SK was an employee of Janssen Scientific Affairs at the time this work was performed; APK, ECH, XLX, SS, PA, BZ, PR, and YZ are employees of Janssen Research & Development; and MS is an employee of Janssen Global Services-these authors own stock or stock options in Johnson & Johnson. Address correspondence to Dr. P. Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's, NL A1C 5B8, Canada. . Accepted for publication April 20, 2021
| | - Alice B Gottlieb
- This study was sponsored by Janssen Research & Development. P. Rahman, MD, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; C.T. Ritchlin, MD, MPH, University of Rochester, Rochester, New York, USA; P.S. Helliwell, PhD, University of Leeds, Leeds, UK; W.H. Boehncke, MD, Geneva University Hospitals, Geneva, Switzerland; P.J. Mease, MD, Swedish Medical Center/Providence St Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A.B. Gottlieb, MD, PhD, Icahn Medical School at Mount Sinai, New York, New York, USA; S. Kafka, MD, Janssen Scientific Affairs, Horsham, Pennsylvania, USA; A.P. Kollmeier, MD, X.L. Xu, PhD, Janssen Research & Development, San Diego, California, USA; E.C. Hsia, MD, Janssen Research & Development, Spring House, Pennsylvania, USA, and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; M. Shawi, PhD, Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, Pennsylvania, USA; S. Sheng, PhD, P. Agarwal, PhD, B. Zhou, PhD, P. Ramachandran, MD, MPH, Y. Zhuang, PhD, Janssen Research & Development, Spring House, Pennsylvania, USA; I.B. McInnes, MD, PhD, University of Glasgow, Glasgow, UK. CTR has received research support from AbbVie, Amgen, and UCB, and consultant fees from AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received research support from Janssen and Novartis; consultant fees from Abbott, AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB; and speakers bureau support from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. PSH has received consulting fees from Eli Lilly and fees for educational services from Amgen, Janssen, Novartis, and Pfizer. WHB has received research support from Pfizer and consulting fees and speaker bureau support from AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Novartis, and UCB. IBM has received research support from AstraZeneca, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB, and consultant fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Gilead, Janssen, Novartis, and UCB. ABG has received research support from Boehringer Ingelheim, Incyte, Janssen, Novartis, Sun Pharmaceutical Industries, UCB, and XBiotech; honoraria from Amgen, BMS, Celgene, Janssen, LEO Pharma, Novartis, and UCB Pharma; consultant fees from AnaptysBio, Avotres, Boehringer Ingelheim, Incyte, Lilly ICOS, Novartis, Pfizer, and Sun Pharmaceutical Industries; and stock options from XBiotech. PJM has received research support, consulting fees, and speaker bureau support from AbbVie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB. SK was an employee of Janssen Scientific Affairs at the time this work was performed; APK, ECH, XLX, SS, PA, BZ, PR, and YZ are employees of Janssen Research & Development; and MS is an employee of Janssen Global Services-these authors own stock or stock options in Johnson & Johnson. Address correspondence to Dr. P. Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's, NL A1C 5B8, Canada. . Accepted for publication April 20, 2021
| | - Shelly Kafka
- This study was sponsored by Janssen Research & Development. P. Rahman, MD, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; C.T. Ritchlin, MD, MPH, University of Rochester, Rochester, New York, USA; P.S. Helliwell, PhD, University of Leeds, Leeds, UK; W.H. Boehncke, MD, Geneva University Hospitals, Geneva, Switzerland; P.J. Mease, MD, Swedish Medical Center/Providence St Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A.B. Gottlieb, MD, PhD, Icahn Medical School at Mount Sinai, New York, New York, USA; S. Kafka, MD, Janssen Scientific Affairs, Horsham, Pennsylvania, USA; A.P. Kollmeier, MD, X.L. Xu, PhD, Janssen Research & Development, San Diego, California, USA; E.C. Hsia, MD, Janssen Research & Development, Spring House, Pennsylvania, USA, and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; M. Shawi, PhD, Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, Pennsylvania, USA; S. Sheng, PhD, P. Agarwal, PhD, B. Zhou, PhD, P. Ramachandran, MD, MPH, Y. Zhuang, PhD, Janssen Research & Development, Spring House, Pennsylvania, USA; I.B. McInnes, MD, PhD, University of Glasgow, Glasgow, UK. CTR has received research support from AbbVie, Amgen, and UCB, and consultant fees from AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received research support from Janssen and Novartis; consultant fees from Abbott, AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB; and speakers bureau support from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. PSH has received consulting fees from Eli Lilly and fees for educational services from Amgen, Janssen, Novartis, and Pfizer. WHB has received research support from Pfizer and consulting fees and speaker bureau support from AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Novartis, and UCB. IBM has received research support from AstraZeneca, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB, and consultant fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Gilead, Janssen, Novartis, and UCB. ABG has received research support from Boehringer Ingelheim, Incyte, Janssen, Novartis, Sun Pharmaceutical Industries, UCB, and XBiotech; honoraria from Amgen, BMS, Celgene, Janssen, LEO Pharma, Novartis, and UCB Pharma; consultant fees from AnaptysBio, Avotres, Boehringer Ingelheim, Incyte, Lilly ICOS, Novartis, Pfizer, and Sun Pharmaceutical Industries; and stock options from XBiotech. PJM has received research support, consulting fees, and speaker bureau support from AbbVie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB. SK was an employee of Janssen Scientific Affairs at the time this work was performed; APK, ECH, XLX, SS, PA, BZ, PR, and YZ are employees of Janssen Research & Development; and MS is an employee of Janssen Global Services-these authors own stock or stock options in Johnson & Johnson. Address correspondence to Dr. P. Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's, NL A1C 5B8, Canada. . Accepted for publication April 20, 2021
| | - Alexa P Kollmeier
- This study was sponsored by Janssen Research & Development. P. Rahman, MD, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; C.T. Ritchlin, MD, MPH, University of Rochester, Rochester, New York, USA; P.S. Helliwell, PhD, University of Leeds, Leeds, UK; W.H. Boehncke, MD, Geneva University Hospitals, Geneva, Switzerland; P.J. Mease, MD, Swedish Medical Center/Providence St Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A.B. Gottlieb, MD, PhD, Icahn Medical School at Mount Sinai, New York, New York, USA; S. Kafka, MD, Janssen Scientific Affairs, Horsham, Pennsylvania, USA; A.P. Kollmeier, MD, X.L. Xu, PhD, Janssen Research & Development, San Diego, California, USA; E.C. Hsia, MD, Janssen Research & Development, Spring House, Pennsylvania, USA, and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; M. Shawi, PhD, Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, Pennsylvania, USA; S. Sheng, PhD, P. Agarwal, PhD, B. Zhou, PhD, P. Ramachandran, MD, MPH, Y. Zhuang, PhD, Janssen Research & Development, Spring House, Pennsylvania, USA; I.B. McInnes, MD, PhD, University of Glasgow, Glasgow, UK. CTR has received research support from AbbVie, Amgen, and UCB, and consultant fees from AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received research support from Janssen and Novartis; consultant fees from Abbott, AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB; and speakers bureau support from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. PSH has received consulting fees from Eli Lilly and fees for educational services from Amgen, Janssen, Novartis, and Pfizer. WHB has received research support from Pfizer and consulting fees and speaker bureau support from AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Novartis, and UCB. IBM has received research support from AstraZeneca, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB, and consultant fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Gilead, Janssen, Novartis, and UCB. ABG has received research support from Boehringer Ingelheim, Incyte, Janssen, Novartis, Sun Pharmaceutical Industries, UCB, and XBiotech; honoraria from Amgen, BMS, Celgene, Janssen, LEO Pharma, Novartis, and UCB Pharma; consultant fees from AnaptysBio, Avotres, Boehringer Ingelheim, Incyte, Lilly ICOS, Novartis, Pfizer, and Sun Pharmaceutical Industries; and stock options from XBiotech. PJM has received research support, consulting fees, and speaker bureau support from AbbVie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB. SK was an employee of Janssen Scientific Affairs at the time this work was performed; APK, ECH, XLX, SS, PA, BZ, PR, and YZ are employees of Janssen Research & Development; and MS is an employee of Janssen Global Services-these authors own stock or stock options in Johnson & Johnson. Address correspondence to Dr. P. Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's, NL A1C 5B8, Canada. . Accepted for publication April 20, 2021
| | - Elizabeth C Hsia
- This study was sponsored by Janssen Research & Development. P. Rahman, MD, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; C.T. Ritchlin, MD, MPH, University of Rochester, Rochester, New York, USA; P.S. Helliwell, PhD, University of Leeds, Leeds, UK; W.H. Boehncke, MD, Geneva University Hospitals, Geneva, Switzerland; P.J. Mease, MD, Swedish Medical Center/Providence St Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A.B. Gottlieb, MD, PhD, Icahn Medical School at Mount Sinai, New York, New York, USA; S. Kafka, MD, Janssen Scientific Affairs, Horsham, Pennsylvania, USA; A.P. Kollmeier, MD, X.L. Xu, PhD, Janssen Research & Development, San Diego, California, USA; E.C. Hsia, MD, Janssen Research & Development, Spring House, Pennsylvania, USA, and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; M. Shawi, PhD, Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, Pennsylvania, USA; S. Sheng, PhD, P. Agarwal, PhD, B. Zhou, PhD, P. Ramachandran, MD, MPH, Y. Zhuang, PhD, Janssen Research & Development, Spring House, Pennsylvania, USA; I.B. McInnes, MD, PhD, University of Glasgow, Glasgow, UK. CTR has received research support from AbbVie, Amgen, and UCB, and consultant fees from AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received research support from Janssen and Novartis; consultant fees from Abbott, AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB; and speakers bureau support from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. PSH has received consulting fees from Eli Lilly and fees for educational services from Amgen, Janssen, Novartis, and Pfizer. WHB has received research support from Pfizer and consulting fees and speaker bureau support from AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Novartis, and UCB. IBM has received research support from AstraZeneca, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB, and consultant fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Gilead, Janssen, Novartis, and UCB. ABG has received research support from Boehringer Ingelheim, Incyte, Janssen, Novartis, Sun Pharmaceutical Industries, UCB, and XBiotech; honoraria from Amgen, BMS, Celgene, Janssen, LEO Pharma, Novartis, and UCB Pharma; consultant fees from AnaptysBio, Avotres, Boehringer Ingelheim, Incyte, Lilly ICOS, Novartis, Pfizer, and Sun Pharmaceutical Industries; and stock options from XBiotech. PJM has received research support, consulting fees, and speaker bureau support from AbbVie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB. SK was an employee of Janssen Scientific Affairs at the time this work was performed; APK, ECH, XLX, SS, PA, BZ, PR, and YZ are employees of Janssen Research & Development; and MS is an employee of Janssen Global Services-these authors own stock or stock options in Johnson & Johnson. Address correspondence to Dr. P. Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's, NL A1C 5B8, Canada. . Accepted for publication April 20, 2021
| | - Xie L Xu
- This study was sponsored by Janssen Research & Development. P. Rahman, MD, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; C.T. Ritchlin, MD, MPH, University of Rochester, Rochester, New York, USA; P.S. Helliwell, PhD, University of Leeds, Leeds, UK; W.H. Boehncke, MD, Geneva University Hospitals, Geneva, Switzerland; P.J. Mease, MD, Swedish Medical Center/Providence St Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A.B. Gottlieb, MD, PhD, Icahn Medical School at Mount Sinai, New York, New York, USA; S. Kafka, MD, Janssen Scientific Affairs, Horsham, Pennsylvania, USA; A.P. Kollmeier, MD, X.L. Xu, PhD, Janssen Research & Development, San Diego, California, USA; E.C. Hsia, MD, Janssen Research & Development, Spring House, Pennsylvania, USA, and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; M. Shawi, PhD, Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, Pennsylvania, USA; S. Sheng, PhD, P. Agarwal, PhD, B. Zhou, PhD, P. Ramachandran, MD, MPH, Y. Zhuang, PhD, Janssen Research & Development, Spring House, Pennsylvania, USA; I.B. McInnes, MD, PhD, University of Glasgow, Glasgow, UK. CTR has received research support from AbbVie, Amgen, and UCB, and consultant fees from AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received research support from Janssen and Novartis; consultant fees from Abbott, AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB; and speakers bureau support from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. PSH has received consulting fees from Eli Lilly and fees for educational services from Amgen, Janssen, Novartis, and Pfizer. WHB has received research support from Pfizer and consulting fees and speaker bureau support from AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Novartis, and UCB. IBM has received research support from AstraZeneca, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB, and consultant fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Gilead, Janssen, Novartis, and UCB. ABG has received research support from Boehringer Ingelheim, Incyte, Janssen, Novartis, Sun Pharmaceutical Industries, UCB, and XBiotech; honoraria from Amgen, BMS, Celgene, Janssen, LEO Pharma, Novartis, and UCB Pharma; consultant fees from AnaptysBio, Avotres, Boehringer Ingelheim, Incyte, Lilly ICOS, Novartis, Pfizer, and Sun Pharmaceutical Industries; and stock options from XBiotech. PJM has received research support, consulting fees, and speaker bureau support from AbbVie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB. SK was an employee of Janssen Scientific Affairs at the time this work was performed; APK, ECH, XLX, SS, PA, BZ, PR, and YZ are employees of Janssen Research & Development; and MS is an employee of Janssen Global Services-these authors own stock or stock options in Johnson & Johnson. Address correspondence to Dr. P. Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's, NL A1C 5B8, Canada. . Accepted for publication April 20, 2021
| | - May Shawi
- This study was sponsored by Janssen Research & Development. P. Rahman, MD, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; C.T. Ritchlin, MD, MPH, University of Rochester, Rochester, New York, USA; P.S. Helliwell, PhD, University of Leeds, Leeds, UK; W.H. Boehncke, MD, Geneva University Hospitals, Geneva, Switzerland; P.J. Mease, MD, Swedish Medical Center/Providence St Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A.B. Gottlieb, MD, PhD, Icahn Medical School at Mount Sinai, New York, New York, USA; S. Kafka, MD, Janssen Scientific Affairs, Horsham, Pennsylvania, USA; A.P. Kollmeier, MD, X.L. Xu, PhD, Janssen Research & Development, San Diego, California, USA; E.C. Hsia, MD, Janssen Research & Development, Spring House, Pennsylvania, USA, and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; M. Shawi, PhD, Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, Pennsylvania, USA; S. Sheng, PhD, P. Agarwal, PhD, B. Zhou, PhD, P. Ramachandran, MD, MPH, Y. Zhuang, PhD, Janssen Research & Development, Spring House, Pennsylvania, USA; I.B. McInnes, MD, PhD, University of Glasgow, Glasgow, UK. CTR has received research support from AbbVie, Amgen, and UCB, and consultant fees from AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received research support from Janssen and Novartis; consultant fees from Abbott, AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB; and speakers bureau support from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. PSH has received consulting fees from Eli Lilly and fees for educational services from Amgen, Janssen, Novartis, and Pfizer. WHB has received research support from Pfizer and consulting fees and speaker bureau support from AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Novartis, and UCB. IBM has received research support from AstraZeneca, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB, and consultant fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Gilead, Janssen, Novartis, and UCB. ABG has received research support from Boehringer Ingelheim, Incyte, Janssen, Novartis, Sun Pharmaceutical Industries, UCB, and XBiotech; honoraria from Amgen, BMS, Celgene, Janssen, LEO Pharma, Novartis, and UCB Pharma; consultant fees from AnaptysBio, Avotres, Boehringer Ingelheim, Incyte, Lilly ICOS, Novartis, Pfizer, and Sun Pharmaceutical Industries; and stock options from XBiotech. PJM has received research support, consulting fees, and speaker bureau support from AbbVie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB. SK was an employee of Janssen Scientific Affairs at the time this work was performed; APK, ECH, XLX, SS, PA, BZ, PR, and YZ are employees of Janssen Research & Development; and MS is an employee of Janssen Global Services-these authors own stock or stock options in Johnson & Johnson. Address correspondence to Dr. P. Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's, NL A1C 5B8, Canada. . Accepted for publication April 20, 2021
| | - Shihong Sheng
- This study was sponsored by Janssen Research & Development. P. Rahman, MD, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; C.T. Ritchlin, MD, MPH, University of Rochester, Rochester, New York, USA; P.S. Helliwell, PhD, University of Leeds, Leeds, UK; W.H. Boehncke, MD, Geneva University Hospitals, Geneva, Switzerland; P.J. Mease, MD, Swedish Medical Center/Providence St Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A.B. Gottlieb, MD, PhD, Icahn Medical School at Mount Sinai, New York, New York, USA; S. Kafka, MD, Janssen Scientific Affairs, Horsham, Pennsylvania, USA; A.P. Kollmeier, MD, X.L. Xu, PhD, Janssen Research & Development, San Diego, California, USA; E.C. Hsia, MD, Janssen Research & Development, Spring House, Pennsylvania, USA, and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; M. Shawi, PhD, Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, Pennsylvania, USA; S. Sheng, PhD, P. Agarwal, PhD, B. Zhou, PhD, P. Ramachandran, MD, MPH, Y. Zhuang, PhD, Janssen Research & Development, Spring House, Pennsylvania, USA; I.B. McInnes, MD, PhD, University of Glasgow, Glasgow, UK. CTR has received research support from AbbVie, Amgen, and UCB, and consultant fees from AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received research support from Janssen and Novartis; consultant fees from Abbott, AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB; and speakers bureau support from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. PSH has received consulting fees from Eli Lilly and fees for educational services from Amgen, Janssen, Novartis, and Pfizer. WHB has received research support from Pfizer and consulting fees and speaker bureau support from AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Novartis, and UCB. IBM has received research support from AstraZeneca, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB, and consultant fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Gilead, Janssen, Novartis, and UCB. ABG has received research support from Boehringer Ingelheim, Incyte, Janssen, Novartis, Sun Pharmaceutical Industries, UCB, and XBiotech; honoraria from Amgen, BMS, Celgene, Janssen, LEO Pharma, Novartis, and UCB Pharma; consultant fees from AnaptysBio, Avotres, Boehringer Ingelheim, Incyte, Lilly ICOS, Novartis, Pfizer, and Sun Pharmaceutical Industries; and stock options from XBiotech. PJM has received research support, consulting fees, and speaker bureau support from AbbVie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB. SK was an employee of Janssen Scientific Affairs at the time this work was performed; APK, ECH, XLX, SS, PA, BZ, PR, and YZ are employees of Janssen Research & Development; and MS is an employee of Janssen Global Services-these authors own stock or stock options in Johnson & Johnson. Address correspondence to Dr. P. Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's, NL A1C 5B8, Canada. . Accepted for publication April 20, 2021
| | - Prasheen Agarwal
- This study was sponsored by Janssen Research & Development. P. Rahman, MD, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; C.T. Ritchlin, MD, MPH, University of Rochester, Rochester, New York, USA; P.S. Helliwell, PhD, University of Leeds, Leeds, UK; W.H. Boehncke, MD, Geneva University Hospitals, Geneva, Switzerland; P.J. Mease, MD, Swedish Medical Center/Providence St Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A.B. Gottlieb, MD, PhD, Icahn Medical School at Mount Sinai, New York, New York, USA; S. Kafka, MD, Janssen Scientific Affairs, Horsham, Pennsylvania, USA; A.P. Kollmeier, MD, X.L. Xu, PhD, Janssen Research & Development, San Diego, California, USA; E.C. Hsia, MD, Janssen Research & Development, Spring House, Pennsylvania, USA, and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; M. Shawi, PhD, Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, Pennsylvania, USA; S. Sheng, PhD, P. Agarwal, PhD, B. Zhou, PhD, P. Ramachandran, MD, MPH, Y. Zhuang, PhD, Janssen Research & Development, Spring House, Pennsylvania, USA; I.B. McInnes, MD, PhD, University of Glasgow, Glasgow, UK. CTR has received research support from AbbVie, Amgen, and UCB, and consultant fees from AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received research support from Janssen and Novartis; consultant fees from Abbott, AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB; and speakers bureau support from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. PSH has received consulting fees from Eli Lilly and fees for educational services from Amgen, Janssen, Novartis, and Pfizer. WHB has received research support from Pfizer and consulting fees and speaker bureau support from AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Novartis, and UCB. IBM has received research support from AstraZeneca, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB, and consultant fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Gilead, Janssen, Novartis, and UCB. ABG has received research support from Boehringer Ingelheim, Incyte, Janssen, Novartis, Sun Pharmaceutical Industries, UCB, and XBiotech; honoraria from Amgen, BMS, Celgene, Janssen, LEO Pharma, Novartis, and UCB Pharma; consultant fees from AnaptysBio, Avotres, Boehringer Ingelheim, Incyte, Lilly ICOS, Novartis, Pfizer, and Sun Pharmaceutical Industries; and stock options from XBiotech. PJM has received research support, consulting fees, and speaker bureau support from AbbVie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB. SK was an employee of Janssen Scientific Affairs at the time this work was performed; APK, ECH, XLX, SS, PA, BZ, PR, and YZ are employees of Janssen Research & Development; and MS is an employee of Janssen Global Services-these authors own stock or stock options in Johnson & Johnson. Address correspondence to Dr. P. Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's, NL A1C 5B8, Canada. . Accepted for publication April 20, 2021
| | - Bei Zhou
- This study was sponsored by Janssen Research & Development. P. Rahman, MD, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; C.T. Ritchlin, MD, MPH, University of Rochester, Rochester, New York, USA; P.S. Helliwell, PhD, University of Leeds, Leeds, UK; W.H. Boehncke, MD, Geneva University Hospitals, Geneva, Switzerland; P.J. Mease, MD, Swedish Medical Center/Providence St Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A.B. Gottlieb, MD, PhD, Icahn Medical School at Mount Sinai, New York, New York, USA; S. Kafka, MD, Janssen Scientific Affairs, Horsham, Pennsylvania, USA; A.P. Kollmeier, MD, X.L. Xu, PhD, Janssen Research & Development, San Diego, California, USA; E.C. Hsia, MD, Janssen Research & Development, Spring House, Pennsylvania, USA, and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; M. Shawi, PhD, Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, Pennsylvania, USA; S. Sheng, PhD, P. Agarwal, PhD, B. Zhou, PhD, P. Ramachandran, MD, MPH, Y. Zhuang, PhD, Janssen Research & Development, Spring House, Pennsylvania, USA; I.B. McInnes, MD, PhD, University of Glasgow, Glasgow, UK. CTR has received research support from AbbVie, Amgen, and UCB, and consultant fees from AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received research support from Janssen and Novartis; consultant fees from Abbott, AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB; and speakers bureau support from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. PSH has received consulting fees from Eli Lilly and fees for educational services from Amgen, Janssen, Novartis, and Pfizer. WHB has received research support from Pfizer and consulting fees and speaker bureau support from AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Novartis, and UCB. IBM has received research support from AstraZeneca, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB, and consultant fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Gilead, Janssen, Novartis, and UCB. ABG has received research support from Boehringer Ingelheim, Incyte, Janssen, Novartis, Sun Pharmaceutical Industries, UCB, and XBiotech; honoraria from Amgen, BMS, Celgene, Janssen, LEO Pharma, Novartis, and UCB Pharma; consultant fees from AnaptysBio, Avotres, Boehringer Ingelheim, Incyte, Lilly ICOS, Novartis, Pfizer, and Sun Pharmaceutical Industries; and stock options from XBiotech. PJM has received research support, consulting fees, and speaker bureau support from AbbVie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB. SK was an employee of Janssen Scientific Affairs at the time this work was performed; APK, ECH, XLX, SS, PA, BZ, PR, and YZ are employees of Janssen Research & Development; and MS is an employee of Janssen Global Services-these authors own stock or stock options in Johnson & Johnson. Address correspondence to Dr. P. Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's, NL A1C 5B8, Canada. . Accepted for publication April 20, 2021
| | - Paraneedharan Ramachandran
- This study was sponsored by Janssen Research & Development. P. Rahman, MD, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; C.T. Ritchlin, MD, MPH, University of Rochester, Rochester, New York, USA; P.S. Helliwell, PhD, University of Leeds, Leeds, UK; W.H. Boehncke, MD, Geneva University Hospitals, Geneva, Switzerland; P.J. Mease, MD, Swedish Medical Center/Providence St Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A.B. Gottlieb, MD, PhD, Icahn Medical School at Mount Sinai, New York, New York, USA; S. Kafka, MD, Janssen Scientific Affairs, Horsham, Pennsylvania, USA; A.P. Kollmeier, MD, X.L. Xu, PhD, Janssen Research & Development, San Diego, California, USA; E.C. Hsia, MD, Janssen Research & Development, Spring House, Pennsylvania, USA, and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; M. Shawi, PhD, Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, Pennsylvania, USA; S. Sheng, PhD, P. Agarwal, PhD, B. Zhou, PhD, P. Ramachandran, MD, MPH, Y. Zhuang, PhD, Janssen Research & Development, Spring House, Pennsylvania, USA; I.B. McInnes, MD, PhD, University of Glasgow, Glasgow, UK. CTR has received research support from AbbVie, Amgen, and UCB, and consultant fees from AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received research support from Janssen and Novartis; consultant fees from Abbott, AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB; and speakers bureau support from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. PSH has received consulting fees from Eli Lilly and fees for educational services from Amgen, Janssen, Novartis, and Pfizer. WHB has received research support from Pfizer and consulting fees and speaker bureau support from AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Novartis, and UCB. IBM has received research support from AstraZeneca, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB, and consultant fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Gilead, Janssen, Novartis, and UCB. ABG has received research support from Boehringer Ingelheim, Incyte, Janssen, Novartis, Sun Pharmaceutical Industries, UCB, and XBiotech; honoraria from Amgen, BMS, Celgene, Janssen, LEO Pharma, Novartis, and UCB Pharma; consultant fees from AnaptysBio, Avotres, Boehringer Ingelheim, Incyte, Lilly ICOS, Novartis, Pfizer, and Sun Pharmaceutical Industries; and stock options from XBiotech. PJM has received research support, consulting fees, and speaker bureau support from AbbVie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB. SK was an employee of Janssen Scientific Affairs at the time this work was performed; APK, ECH, XLX, SS, PA, BZ, PR, and YZ are employees of Janssen Research & Development; and MS is an employee of Janssen Global Services-these authors own stock or stock options in Johnson & Johnson. Address correspondence to Dr. P. Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's, NL A1C 5B8, Canada. . Accepted for publication April 20, 2021
| | - Yanli Zhuang
- This study was sponsored by Janssen Research & Development. P. Rahman, MD, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; C.T. Ritchlin, MD, MPH, University of Rochester, Rochester, New York, USA; P.S. Helliwell, PhD, University of Leeds, Leeds, UK; W.H. Boehncke, MD, Geneva University Hospitals, Geneva, Switzerland; P.J. Mease, MD, Swedish Medical Center/Providence St Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A.B. Gottlieb, MD, PhD, Icahn Medical School at Mount Sinai, New York, New York, USA; S. Kafka, MD, Janssen Scientific Affairs, Horsham, Pennsylvania, USA; A.P. Kollmeier, MD, X.L. Xu, PhD, Janssen Research & Development, San Diego, California, USA; E.C. Hsia, MD, Janssen Research & Development, Spring House, Pennsylvania, USA, and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; M. Shawi, PhD, Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, Pennsylvania, USA; S. Sheng, PhD, P. Agarwal, PhD, B. Zhou, PhD, P. Ramachandran, MD, MPH, Y. Zhuang, PhD, Janssen Research & Development, Spring House, Pennsylvania, USA; I.B. McInnes, MD, PhD, University of Glasgow, Glasgow, UK. CTR has received research support from AbbVie, Amgen, and UCB, and consultant fees from AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received research support from Janssen and Novartis; consultant fees from Abbott, AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB; and speakers bureau support from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. PSH has received consulting fees from Eli Lilly and fees for educational services from Amgen, Janssen, Novartis, and Pfizer. WHB has received research support from Pfizer and consulting fees and speaker bureau support from AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Novartis, and UCB. IBM has received research support from AstraZeneca, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB, and consultant fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Gilead, Janssen, Novartis, and UCB. ABG has received research support from Boehringer Ingelheim, Incyte, Janssen, Novartis, Sun Pharmaceutical Industries, UCB, and XBiotech; honoraria from Amgen, BMS, Celgene, Janssen, LEO Pharma, Novartis, and UCB Pharma; consultant fees from AnaptysBio, Avotres, Boehringer Ingelheim, Incyte, Lilly ICOS, Novartis, Pfizer, and Sun Pharmaceutical Industries; and stock options from XBiotech. PJM has received research support, consulting fees, and speaker bureau support from AbbVie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB. SK was an employee of Janssen Scientific Affairs at the time this work was performed; APK, ECH, XLX, SS, PA, BZ, PR, and YZ are employees of Janssen Research & Development; and MS is an employee of Janssen Global Services-these authors own stock or stock options in Johnson & Johnson. Address correspondence to Dr. P. Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's, NL A1C 5B8, Canada. . Accepted for publication April 20, 2021
| | - Iain B McInnes
- This study was sponsored by Janssen Research & Development. P. Rahman, MD, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; C.T. Ritchlin, MD, MPH, University of Rochester, Rochester, New York, USA; P.S. Helliwell, PhD, University of Leeds, Leeds, UK; W.H. Boehncke, MD, Geneva University Hospitals, Geneva, Switzerland; P.J. Mease, MD, Swedish Medical Center/Providence St Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA; A.B. Gottlieb, MD, PhD, Icahn Medical School at Mount Sinai, New York, New York, USA; S. Kafka, MD, Janssen Scientific Affairs, Horsham, Pennsylvania, USA; A.P. Kollmeier, MD, X.L. Xu, PhD, Janssen Research & Development, San Diego, California, USA; E.C. Hsia, MD, Janssen Research & Development, Spring House, Pennsylvania, USA, and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; M. Shawi, PhD, Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, Pennsylvania, USA; S. Sheng, PhD, P. Agarwal, PhD, B. Zhou, PhD, P. Ramachandran, MD, MPH, Y. Zhuang, PhD, Janssen Research & Development, Spring House, Pennsylvania, USA; I.B. McInnes, MD, PhD, University of Glasgow, Glasgow, UK. CTR has received research support from AbbVie, Amgen, and UCB, and consultant fees from AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received research support from Janssen and Novartis; consultant fees from Abbott, AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB; and speakers bureau support from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. PSH has received consulting fees from Eli Lilly and fees for educational services from Amgen, Janssen, Novartis, and Pfizer. WHB has received research support from Pfizer and consulting fees and speaker bureau support from AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Eli Lilly, Novartis, and UCB. IBM has received research support from AstraZeneca, BMS, Celgene, Janssen, Eli Lilly, Novartis, and UCB, and consultant fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Gilead, Janssen, Novartis, and UCB. ABG has received research support from Boehringer Ingelheim, Incyte, Janssen, Novartis, Sun Pharmaceutical Industries, UCB, and XBiotech; honoraria from Amgen, BMS, Celgene, Janssen, LEO Pharma, Novartis, and UCB Pharma; consultant fees from AnaptysBio, Avotres, Boehringer Ingelheim, Incyte, Lilly ICOS, Novartis, Pfizer, and Sun Pharmaceutical Industries; and stock options from XBiotech. PJM has received research support, consulting fees, and speaker bureau support from AbbVie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB. SK was an employee of Janssen Scientific Affairs at the time this work was performed; APK, ECH, XLX, SS, PA, BZ, PR, and YZ are employees of Janssen Research & Development; and MS is an employee of Janssen Global Services-these authors own stock or stock options in Johnson & Johnson. Address correspondence to Dr. P. Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's, NL A1C 5B8, Canada. . Accepted for publication April 20, 2021
| |
Collapse
|